Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy.

Nassiba TaibMaysaloun MerhiVarghese InchakalodySarra MestiriShereena HydroseKarama Makni-MaalejAfsheen RazaFairooz SahirFouad AziziParveen B NizamuddinQueenie FernandesZeenath Safira K M YoosufSalam AlmoghrabiLobna Al-ZaidanAlaaeldin ShablakShahab UddinCristina MaccalliMohammed Ussama Al HomsiSaid Dermime

Published in: Journal of translational medicine (2023)

We conclude that the upregulation of both stemness and immune checkpoint markers by DAC treatment on CRC cells might represent a mechanism of immune evasion. In addition, induction of NY-ESO-1 may represent an immuno-therapeutic option in metastatic CRC patients. Finally, the combination of DAC and anti-PD-1/anti-PD-L1 antibodies treatment should represent a potential therapeutic intervention for this group of patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
randomized controlled trial
epithelial mesenchymal transition
squamous cell carcinoma
small cell lung cancer
poor prognosis
peritoneal dialysis
induced apoptosis
cell proliferation
patient reported outcomes
combination therapy